metaEvidence - overview


			deaths (OS)
endometrial cancer endometrial cancer
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.82 [0.63; 1.07], 1 RCT, I2=0% inconclusive result
	dostarlimab plus soC vs. placebo plus SoC	2	0.69 [0.54; 0.89], 1 RCT, I2=0% conclusive unassessable degree of certainty
	durvalumab plus olaparib plus SoC vs. placebo plus SoC	1	0.59 [0.42; 0.83], 1 RCT, I2=0% unassessable degree of certainty
	durvalumab plus SoC vs. placebo plus SoC	1	0.77 [0.56; 1.06], 1 RCT, I2=0% inconclusive result
	pembrolizumab plus SoC vs. placebo plus SoC	2	-
versus Standard of Care (SoC)
	avelumab plus SoC vs. Standard of Care (SoC)	1	1.13 [0.62; 2.06], 1 RCT, I2=0% inconclusive result
	pembrolizumab plus lenvatinib vs. Standard of Care (SoC)	2	0.78 [0.55; 1.10], 2 RCTs, I2=87% inconclusive result
endometrial cancer - (neo)adjuvant (NA) endometrial cancer - (neo)adjuvant (NA)